QGEN - QIAGEN N.V.
| Previous Close | 0.00 |
| Open | 38.40 |
| Bid | 38.32 x 800 |
| Ask | 38.33 x 1400 |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | 749,003 |
| Avg. Volume | 1,296,465 |
| Market Cap | 8.727B |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | 47.47 |
| EPS (TTM) | 0.81 |
| Earnings Date | Jul 29, 2019 - Aug 2, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.89 |
- Zacks•19 hours ago
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
- Business Wire•2 days ago
QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation
New breakthrough test for low-resource, high-burden regions to help in global fight against tuberculosis
- Markit•3 days ago
See what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGENView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for QGEN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting QGEN. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.19 billion over the last one-month into ETFs that hold QGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Associated Press•3 days ago
Sprint and Qiagen rise while Apple and Dish decline
Stocks that moved substantially or traded heavily on Monday: Alphabet Inc., down $24.12 to $1,144.66 The parent of search engine Google warned that some of its features could lose support on Huawei mobile ...
- Benzinga•4 days ago
Qiagen Snags FDA Nod For Molecular Diagnostic System, Announces US Launch
Qiagen NV (NYSE: QGEN ) shares were spiking higher Monday following the announcement of FDA approval for its molecular diagnostic testing system. What Happened Germany-based Qiagen, a provider of sample ...
- Zacks•7 days ago
QIAGEN Partners Inovio to Develop Companion Diagnostics
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
- Benzinga•7 days ago
The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- PR Newswire•7 days ago
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
- Business Wire•7 days ago
QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions
Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
- Motley Fool•11 days ago
Qiagen Looks to Growth in the Second Half of the Year
The QIAstat should accelerate growth for the diagnostic testing company.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of QGEN earnings conference call or presentation 7-May-19 1:00pm GMT
Q1 2019 Qiagen NV Earnings Call
- Simply Wall St.•14 days ago
With A 7.2% Return On Equity, Is QIAGEN N.V. (NYSE:QGEN) A Quality Stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire•14 days ago
QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
QIAGEN N.V. announces that it will initiate the repurchase of a fourth tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 10, 2019 until June 18, 2019, at the latest, a fourth tranche of up to 2 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
- GuruFocus.com•16 days ago
Bank of Italy Buys Qiagen NV
Rome, L6, based Investment company Bank of Italy buys Qiagen NV during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Bank of Italy.
Motley Fool•16 days agoQiagen NV (QGEN) Q1 2019 Earnings Call Transcript
QGEN earnings call for the period ending March 31, 2019.
- Zacks•17 days ago
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
- Zacks•17 days ago
Qiagen (QGEN) Tops Q1 Earnings Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 3.85% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•17 days ago
Qiagen: 1Q Earnings Snapshot
The Venlo, Netherlands-based company said it had profit of 13 cents per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, were 27 cents per share. The results ...
- Business Wire•17 days ago
QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program
QIAGEN reports results for first quarter of 2019 and announces plans for new $100 million share repurchase program
- Zacks•21 days ago
Why Earnings Season Could Be Great for QIAGEN (QGEN)
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Business Wire•21 days ago
QIAGEN Posts 2018 Annual Report on Its Website
QIAGEN N.V. announced today that it had posted its 2018 Annual Report on its website at http://financialreport.qiagen.com.
